Dr. Albert Bourla: Thank you, Angela. And also to emphasize that the 12 million, calculation is a global number, not a U.S. number. It’s a global number. So, I believe the 9 million of IQVIA is approximately in the U.S. And — but I don’t know if they have also estimations for outside the U.S. So, next question, please. I’m sorry for the — it’s a global number, excluding China, well that I mentioned. Next question, please.
Operator: Our next question will come from Geoff Meacham with Bank of America.
Geoff Meacham: Just have two. The first one is on COVID. When you look at the 2023 demand and beyond really for both products, I guess, I’m trying to better understand the volume side of the equation. Are you guys baking in the emergence of, say, a new variant or maybe a change in behavior towards boosters? That’s the first question. The second one is, from a BD perspective, Albert, you have a lot of cash to deploy. If your COVID assumptions don’t quite play out, does that inform the number of deals or the size of deals? I guess, I’m trying to get a view about where BD fits in your strategic priorities. Thank you.
Dr. Albert Bourla: Of course. First, what is the assumption about the disease because that’s a fundamental assumption behind all these projections that we are doing. It is that the disease will continue in the foreseeable future, manifesting clinically the same way that it has the last 6 to 9 months. So there will be mutations and there will be infections over there. And — but the vaccination rates will be coming down because of lack of compliance but will stabilize to a certain degree of people, but they believe in vaccinations and they feel they are at high risk and they want to make their vaccines. At the same time, the infections were slightly going up because when you have waning immune protection for the population, then you will see more infections are actually more severe infections.
So, these are the assumptions that we are using. We are not using assumptions that all the variants will have — will escape in the protection of the vaccine. But we are using the assumptions that people will be getting 1.3 in the beginning and then going down 1.1, 1.2 doses per year as a normal booster. What was the second question? On the BD, yes, clearly, business development is, by far, one of our biggest priorities, something that I personally take care of and something that we have a very big team screening all the opportunities. I would like to ask Aamir, who is responsible for that area, to make some comments about our priorities.
Aamir Malik: So, Geoff, specifically to your question, you heard Albert described, we set this aspiration goal of $25 billion in 2030 from BD. We’re over 40% of the way there with approximately $10.5 billion of that number through the deals that we’ve done. And we feel very confident that we’ve got the financial flexibility on the balance sheet and the firepower to complete what we need to, to achieve that goal. And we’re going to continue to be disciplined about how we pursue that.
Dr. Albert Bourla: I think we can move to the next question.
Operator: Our next question will come from Steve Scala with Cowen.
Steve Scala: Thank you. I have a couple of questions. On page 4 of the release, Pfizer reiterated that non-COVID revenue growth in 2023 will be 7% to 9% and anticipates it will be split between launch, acquired and in-line products. That implies about $3.5 billion in incremental revenue growth. But in 2022, Prevnar alone grew $1 billion, and Eliquis and Vyndaqel together added another $1 billion. So with the launch in acquired products growing well, what does this guidance imply for the base business in 2023? It seems like a substantial slowdown is implied in the base business in the current year. Second question, has Pfizer learned anything from the Zeposia performance to date that would either increase or decrease its confidence in etrasimod? Thank you very much.
